Session Details
[1-S]Frontline strategies for medicate of Alzheimer's Disease
Mon. Mar 16, 2026 8:30 AM - 10:00 AM JST
Mon. Mar 16, 2026 11:30 PM - 1:00 AM UTC
Mon. Mar 16, 2026 11:30 PM - 1:00 AM UTC
Room 2(A200)
Chair:Atsumi Nitta(University of Toyama), Minako Hoshi(Kyoto University)
While cancer treatment has made revolutionary progress over the past decade, development of drugs in the field of neurology remains a major challenge for us. In particular, there has been no groundbreaking treatment for Alzheimer's disease so far. In recent years, Lecanemab and Donanemab, which work by removing amyloid-beta plaques, have been approved, marking a new phase in Alzheimer's disease treatment. In this symposium, we will present the latest research, including the outlook for novel drugs improvements in dementia independent of amyloid-beta, changes in endothelial cells in the Alzheimer's disease brain and their relation to amyloid-beta, as well as clinical development strategies for novel therapies.
[1-S-01]Development of new treatments for Alzheimer's disease
*Minako Hoshi1 (1. Kyoto University)
[1-S-02]Mechanisms by which neurovascular crosstalk disruption exacerbates neuronal Aβ and tau pathology
*Tomoya Sasahara1 (1. Foundation for Biomedical Research and Innovation at Kobe)
[1-S-03]Function of Shati/Nat8l on the Alzheimer's disease model
*Atsumi Nitta1, Miho Takakuwa1, Naotaka Izuo1,2, Jun Yokose1, Yusuke Yano1 (1. University of Toyama, 2. University of Tokyo)
[1-S-04]Current status and prospects of anti-amyloid therapy
*Kenjiro Ono1 (1. Kanazawa University Graduate School of Medical Sciences)